Prempro news | Breaking Prempro news | Prempro

Update 3: Wyeth's Q2 Profit Climbs on Drug Sales

...Bernard Poussot, head of global pharmaceutical operations, said that the low-dose Wyeth just launched ads urging women to talk to their doctors about menopause symptoms, something many stopped doing after the negative studies were released.

The company repeated its recent full-year guidance for earnings of $2.80 to $2.90 per share, excluding any one-time costs.

Analysts are forecasting $2.86.

"If current strong business trends continue, full-year earnings are more likely to approach or exceed the upper end," Martin said.

That's despite plans to increase research spending substantially in the second half of the year.

Wyeth shares rose $1.05, or 2.3 percent, to $46.05 in early afternoon trading on the New York Stock Exchange, above their 52-week high of $45.76 reached earlier this month.

E-mail RSS '); //- Free Trial Issue of Forbes Forbes Gift Subscription Subscribe To Newsletters Subscriber Customer Service ForbesAutos.com more Book Review A Basketball Miracle Book Review Deal Killer J...

Read more...

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news

Health and Fitness